Astellas, Pfizer Sue to Block Copies of Lucrative Xtandi Drug

Astellas Pharma Inc., Pfizer Inc.’s Medivation, and the University of California allege in a federal lawsuit that copies of Xtandi proposed by Qilu Pharmaceutical Co. infringe two patents for the blockbuster prostate cancer drug.

Qilu’s generic version infringes US Patent Nos. 7,709,517 and 11,839,689, according to a complaint filed Thursday in the US District Court for the District of New Jersey. The ‘517 patent was part of a case against Sun Pharmaceutical Industries Ltd. that settled last October. The ‘689 patent expires in September 2033, the latest of the four patents listed for listed for Xtandi in the ...